Handelsavisen
prelaunch
Companies Basic Materials ORTHEX.HE
OR
ORTHEX.HE Nasdaq Helsinki Commodity Chemicals

Orthex Oyj

€4,35
Open in Charts → Attach watcher ⌖
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
77,3M EUR
P/E
11,3x
EV / Rev
1,1x
Div yield
5,22 %
Op margin
12,5 %
ROE
4,5 %
Net margin
7,1 %
Debt / equity
0,86
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Orthex Oyj is a Finnish company that produces and sells chemical products, primarily serving the industrial and consumer goods sectors.

Business. Orthex Oyj (ORTHEX.HE) is a Finnish company operating in the commodity chemicals industry within the broader chemicals sector. The firm is headquartered in Finland and is primarily listed on the Nasdaq Helsinki exchange. As specific segment and geographic breakdowns are not provided, the company is described at the industry level as a participant in the commodity chemicals market.

Classification92 %
SectorBasic Materials
Business sectorChemicals
IndustryCommodity Chemicals
ActivityChemicals
Generated · model-assisted
Sell-side consensus
HOLD3 analysts
1 buy1 hold1 sell
Avg 12m price target5,30

Analyst recommendations

3 analysts · consensus Hold
Buy1
Hold1
Sell1
12-month price target
5,30
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
11,3x
P/E
Analysts
Hold
3 analysts · indicative
Ownership
not yet wired
Profitability
4,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ORTHEX.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials · THIS SECTOR+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ORTHEX.HE. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Orthex Oyj (ORTHEX.HE) is a Finnish company operating in the commodity chemicals industry within the broader chemicals sector. The firm is headquartered in Finland and is primarily listed on the Nasdaq Helsinki exchange. As specific segment and geographic breakdowns are not provided, the company is described at the industry level as a participant in the commodity chemicals market.

    Classification92 %
    SectorBasic Materials
    Business sectorChemicals
    IndustryCommodity Chemicals
    ActivityChemicals
    AI synthesis
    GENERATED

    Orthex Oyj maintains a market capitalization of EUR 76.72 million and a price-to-earnings ratio of 49.08, indicating a relatively high valuation compared to its earnings. The company's price-to-book ratio of 2.2 suggests that the market values the company at twice its book value, which is a common multiple in the chemicals industry. The enterprise value to EBITDA ratio of 33.59 is significantly higher than the typical range for commodity chemicals, indicating that the company is trading at a premium relative to its operating performance.

    In terms of profitability, Orthex reports a return on equity of 4.48% and a return on assets of 1.83%, both of which are below the industry median for commodity chemicals. The company's operating margin is 12.54% (calculated as operating income of EUR 2.76 million divided by revenue of EUR 22.01 million), which is also below the industry average. This suggests that Orthex is underperforming its peers in terms of generating returns from its equity and assets.

    Orthex's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. The company's exposure to a single segment increases its vulnerability to market fluctuations in the chemicals industry. There is no information available on geographic revenue distribution, which limits the ability to assess regional risk exposure.

    Looking at the company's growth trajectory, there is no specific outlook provided for the current or next fiscal year. However, the company's free cash flow of EUR 1.58 million and operating cash flow of EUR 4.07 million indicate a positive cash flow position, which supports operational flexibility. The capital expenditure of EUR -1.04 million suggests that the company is not currently investing heavily in new projects or infrastructure.

    The risk assessment for Orthex highlights a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 0.86 indicates a moderate level of leverage, and the current ratio of 2.06 suggests that it has sufficient short-term assets to cover its short-term liabilities. However, the note that net cash is negative after subtracting total debt raises concerns about the company's liquidity position.

    Recent events and disclosures for Orthex include analyst estimates that suggest a mean price target of EUR 5.30, with a median of EUR 5.30 and a range from EUR 5.00 to EUR 5.60. The mean recommendation from analysts is 2.67, indicating a generally positive outlook, with one strong-buy and one hold recommendation.

    Key takeaways
    • Orthex Oyj is valued at a premium relative to its earnings and book value, with a P/E ratio of 49.08 and a P/B ratio of 2.2.
    • The company's return on equity and return on assets are below the industry median, indicating underperformance in profitability.
    • Orthex's revenue is concentrated in a single business segment, increasing its exposure to market volatility.
    • Analysts have a generally positive outlook, with a mean price target of EUR 5.30 and a mean recommendation of 2.67.
    • The company has a moderate level of leverage and a current ratio of 2.06, suggesting acceptable short-term liquidity.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Free cash flow surged nearly 100% year-over-year to EUR 5.1 million, demonstrating strong cash generation capabilities.

    Analysts project 21.8% upside to a mean price target of EUR 5.30, suggesting undervaluation relative to current market price.

    Cash conversion ratio of 2.61 ranks in the top quartile, outperforming the 1.1 cohort median significantly.

    Long-term debt decreased steadily from EUR 35.5 million in 2022 to EUR 24.5 million in 2026, reducing leverage.

    BEAR CASE · 5

    The company faces high credit risk, posing a significant threat to financial stability and potential borrowing costs.

    Debt-to-equity ratio of 0.86 places Orthex in the bottom quartile, indicating excessive leverage compared to peers.

    Revenue declined 2.8% year-over-year to EUR 87.2 million, reflecting a contraction in top-line growth.

    Medium liquidity risk flags potential difficulties in meeting short-term obligations or managing cash flow volatility.

    Return on equity of 4.5% remains modest, suggesting limited efficiency in generating profits from shareholder capital.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-05
    Q4 2025 · Quarter highlights

    Revenue €22.3M, −6,6% YoY; Operating income +10,1% YoY.

    Revenue€22.3M−6,6 % YoY
    Operating income€3.0M+10,1 % YoY
    Net income€2.2M+18,7 % YoY
    Free cash flow€77.0k+7 600,0 % YoY
    EPS
    Operating cash flow€12.3M+4,5 % YoY
    Financials
    Income statement
    Revenue€22.3M
    Gross profit€6.7M
    Operating income€3.0M
    Net income€2.2M
    Margins
    Gross margin30.2%
    Operating margin13.5%
    Net margin9.7%
    FCF margin0.3%
    Balance sheet
    Total assets€86.3M
    Total liabilities€45.9M
    Total equity€40.4M
    Cash & equivalents€11.8M
    Long-term debt€24.5M
    Cash flow
    Operating cash flow€12.3M
    CapEx-€2.7M
    Free cash flow€77.0k
    SBC
    P&L flow · revenue → net income
    Revenue €22.3MOperating costs €19.3MTax €846.0kNet income €2.2M
    Highlights
    • Revenue €22.3M, −6,6% YoY
    • Operating income +10,1% YoY
    • Net income +18,7% YoY
    • Free cash flow +7 600,0% YoY
    • Net margin 9.7%

    Valuation TTM

    Market price
    €4,35
    Market cap
    €76.7M
    Enterprise value
    €92.7M
    P/E
    11.3x
    Non-GAAP P/E
    EV / Revenue
    1.1x
    EV / Op income
    9.5x
    EV / OCF
    22.8x
    P / B
    2.2x
    P / Tangible book
    2.2x
    Tangible book
    €34.9M
    Net cash
    -€16.0M
    Current ratio
    2.1
    Debt / equity
    0.9
    ROA
    1.8%
    ROE
    4.5%
    Cash conversion
    261.0%
    CapEx / revenue
    -4.7%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,32
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    3
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-10 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,32
    Revenueno estimateno estimate90,8M EUR
    Operating incomeno estimateno estimate10,5M EUR
    Full-year consensus mean (period as reported by source) · consensus in EUR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution3 analysts
    Strong buy1
    Buy0
    Hold1
    Sell1
    Strong sell0
    12-month price target€5,30 · Median €5,30
    Low €5,00High €5,60
    Operating income · consensus10,5M EUR
    EPS surprise
    +17,5 %
    reported vs consensus · beat
    Revenue surprise
    −4,0 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low€5,00
    Mean€5,30
    Median€5,30
    High€5,60
    Spot€4,35
    +21.8 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin12,5 %Above P75
    Net Margin7,1 %Above median
    ROE4,5 %Above median
    Capex / Rev-4,7 %Above median
    D/E0,86Bottom quartile
    Cash Conv2,61Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • Orthex Oyj Market data — financials · 2026-05-28
    • Orthex Oyj Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ORTHEX.HECanonical
    Nasdaq Helsinki · EUR

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-03-05 07:00 UTCEARNINGSQuarterly results — Q4 2025 Revenue EUR 22.3M · Net EUR 2.2M
    2026-03-05 07:00 UTCEARNINGSAnnual results — FY 2026 Revenue EUR 87.2M · Net EUR 6.8M
    2025-11-13 07:00 UTCEARNINGSQuarterly results — Q3 2025 Revenue EUR 23.4M · Net EUR 2.4M
    2025-08-21 07:00 UTCEARNINGSQuarterly results — Q2 2025 Revenue EUR 20.5M · Net EUR 0.9M
    2025-05-15 07:00 UTCEARNINGSQuarterly results — Q1 2025 Revenue EUR 21.0M · Net EUR 1.3M
    2025-03-12 07:00 UTCEARNINGSQuarterly results — Q4 2024 Revenue EUR 23.9M · Net EUR 1.8M
    2025-03-12 07:00 UTCEARNINGSAnnual results — FY 2025 Revenue EUR 89.7M · Net EUR 6.1M
    2024-11-15 07:00 UTCEARNINGSQuarterly results — Q3 2024 Revenue EUR 22.8M · Net EUR 1.8M
    2024-08-22 07:01 UTCEARNINGSQuarterly results — Q2 2024 Revenue EUR 21.0M · Net EUR 0.9M
    2024-05-15 17:41 UTCEARNINGSQuarterly results — Q1 2024 Revenue EUR 22.0M · Net EUR 1.6M
    2024-03-05 11:12 UTCEARNINGSAnnual results — FY 2024 Revenue EUR 85.9M · Net EUR 6.9M
    2023-03-08 07:58 UTCEARNINGSAnnual results — FY 2023 Revenue EUR 84.0M · Net EUR 2.1M
    2022-03-09 07:09 UTCEARNINGSAnnual results — FY 2022 Revenue EUR 88.7M · Net EUR 6.0M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage